Progyny, Inc. (NASDAQ:PGNY) Receives Consensus Rating of “Moderate Buy” from Analysts

Progyny, Inc. (NASDAQ:PGNY) has been assigned a consensus recommendation of “Moderate Buy” from the thirteen brokerages that are presently covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation, nine have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokers that have covered the stock in the last year is $33.25.

A number of equities research analysts have recently weighed in on the stock. Barclays restated an “equal weight” rating and issued a $34.00 price objective (up from $27.00) on shares of Progyny in a report on Tuesday, July 28th. Weiss Ratings raised Progyny from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, June 26th. Bank of America raised their price target on Progyny from $29.00 to $31.00 and gave the company a “buy” rating in a research note on Tuesday, June 2nd. Citizens Jmp lifted their price target on Progyny from $30.00 to $31.00 and gave the stock a “market outperform” rating in a report on Monday, May 11th. Finally, Leerink Partners set a $38.00 price objective on Progyny in a research report on Wednesday, July 22nd.

Progyny Stock Performance

Shares of PGNY opened at $30.21 on Friday. Progyny has a 1 year low of $16.10 and a 1 year high of $33.06. The stock has a market capitalization of $2.37 billion, a PE ratio of 39.23, a PEG ratio of 2.49 and a beta of 1.01. The stock has a 50-day simple moving average of $29.02 and a 200-day simple moving average of $23.40.

Progyny (NASDAQ:PGNY) last issued its earnings results on Thursday, August 6th. The company reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.33 by $0.22. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The firm had revenue of $350.51 million for the quarter, compared to analysts’ expectations of $348.63 million. During the same quarter last year, the company earned $0.19 earnings per share. The firm’s revenue was up 5.3% compared to the same quarter last year. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. Analysts predict that Progyny will post 1.19 EPS for the current year.

Progyny announced that its Board of Directors has authorized a stock repurchase program on Tuesday, May 26th that allows the company to buyback $200.00 million in outstanding shares. This buyback authorization allows the company to reacquire up to 10.3% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board believes its shares are undervalued.

Key Headlines Impacting Progyny

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Second-quarter adjusted earnings were $0.55 per share, well above the reported consensus estimates of $0.33 and $0.51, and up from $0.19 a year earlier. Revenue reached $350.5 million, exceeding the $348.6 million consensus estimate and rising 5.3% year over year. Progyny, Inc. Announces Second Quarter 2026 Results
• Positive Sentiment: Progyny raised or reaffirmed a favorable full-year outlook, forecasting 2026 earnings of $2.04–$2.10 per share, above the $1.86 analyst consensus. Full-year revenue guidance of approximately $1.4 billion was broadly in line with expectations. Progyny Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: The quarter showed improved profitability, with reported net margin of 5.23% and return on equity of 13.34%, potentially supporting the company’s earnings trajectory. Progyny Earnings Report and Conference Call
• Neutral Sentiment: Third-quarter EPS guidance of $0.50–$0.52 exceeded the $0.47 consensus, indicating continued earnings strength.
• Negative Sentiment: Third-quarter revenue guidance of $335 million–$345 million fell below the $350.2 million analyst estimate. The softer near-term top-line outlook may have outweighed the earnings beats, particularly with PGNY trading at a relatively elevated valuation and near its 12-month high. Progyny Q2 CY2026 Results and Stock Reaction

Insider Activity

In other Progyny news, Director Kevin K. Gordon sold 5,500 shares of the firm’s stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $24.99, for a total transaction of $137,445.00. Following the sale, the director owned 9,318 shares of the company’s stock, valued at approximately $232,856.82. This trade represents a 37.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Geoffrey Clapp sold 1,530 shares of the business’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $25.58, for a total transaction of $39,137.40. Following the sale, the insider owned 59,117 shares of the company’s stock, valued at $1,512,212.86. This represents a 2.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 36,916 shares of company stock valued at $939,875 over the last 90 days. Insiders own 9.90% of the company’s stock.

Institutional Investors Weigh In On Progyny

Several hedge funds and other institutional investors have recently bought and sold shares of PGNY. Caitong International Asset Management Co. Ltd purchased a new stake in Progyny in the fourth quarter valued at $25,000. Hantz Financial Services Inc. grew its holdings in shares of Progyny by 79.4% during the fourth quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock worth $43,000 after purchasing an additional 742 shares during the last quarter. Quarry LP increased its position in shares of Progyny by 2,004.1% during the third quarter. Quarry LP now owns 3,598 shares of the company’s stock worth $77,000 after purchasing an additional 3,427 shares in the last quarter. Canada Pension Plan Investment Board purchased a new stake in shares of Progyny in the 2nd quarter valued at about $77,000. Finally, New Age Alpha Advisors LLC purchased a new stake in shares of Progyny in the 4th quarter valued at about $94,000. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.